CD99

Across TCGA pan-cancer cohorts, CD99 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CD99 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CD99 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CD99 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

HNSC, LSCC, and UCEC are the cancer types where CD99 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.557	0.785	.012	29	view →
LSCC	DFS	Tertile	II,III,IV	0.494	0.922	<.001	20	view →
UCEC	DFS	Tertile	All	0.972	0.805	.005	8	view →
GBM	OS	Median	All	0.717	0.987	<.001	8	view →
PDAC	OS	Median	IV	0.836	0.491	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CD99–HNSC (OS)

Open the HNSC breakdown →